WE CLAIM:

1. A compound of the formula:

$Z_1X_1X_2EGTX_6ISDYSIX_{13}LDX_{16}X_{17}X_{18}QX_{20}X_{21}X_{22}VX_{24}$

$X_{25}X_{26}L$

$X_{28}X_{29}GPSSGAPPPSZ_2$ (SEQ ID NO:4) wherein:

Z_1 is a modification of the N-terminal amino group wherein the modification is selected from the group consisting of acetyl and absent;

X_1 is selected from the group consisting of Y and D-Tyr;

X_2 is selected from the group consisting of Aib, A, and D-Ala;

X_6 is selected from the group consisting of F, αMeF, Iva, L, αMeL, and αMeF(2F);

X_{13} is selected from the group consisting of αMeL, A, L, and Aib;

X_{16} is selected from the group consisting of K, E, and Orn;

X_{17} is selected from the group consisting of I and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)$_2$-(γ-Glu)-CO-(CH_2)q-CO_2H;

X_{18} is selected from the group consisting of H, A, and R;

X_{20} is selected from the group consisting of Aib and Q;

X_{21} is selected from the group consisting of D and E;

X_{22} is selected from the group consisting of F and αMeF;

X_{24} is selected from the group consisting of E, N, Q, and D-Glu;

X_{25} is selected from the group consisting of Y, 4-Pal, W, and αMeY;

X_{26} is selected from the group consisting of L, and K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)$_2$-(γ-Glu)-CO-(CH_2)q-CO_2H;

X_{28} is selected from the group consisting of E and A;

X_{29} is selected from the group consisting of G, A, Q, and T; q is selected from the group consisting of 16 and 18; and

Z_2 is absent or a modification of the C-terminal group, wherein the modification is amidation;

wherein one and only one selected from X_{17} and X_{26} is K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)$_2$-(γ-Glu)-CO-(CH_2)q-CO_2H; or a pharmaceutically acceptable salt thereof.

2. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 1 wherein X_1 is Y and Z_1 is absent.

3. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 1 or Claim 2 wherein X_2 is Aib.

4. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 3 wherein:
X_6 is selected from the group consisting of F and αMeF(2F).

5. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 4 wherein:
X_{13} is selected from the group consisting of L and αMeL.

6. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 5 wherein X_{16} is K or Orn.

7. A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 6 wherein X_{16} is K.

8. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 7 wherein X_{18} is H.

9. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 8 wherein X_{20} is Aib; and X_{22} is F.

10. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 9 wherein X_{21} is D.

11. A compound, or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 10 wherein X_{25} is 4-Pal or Y.

12. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 10 wherein:
X_{17} is K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)$_2$-(γ-Glu)-CO-(CH_2)q-CO_2H; and X_{26} is L.

13. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 10 wherein X_{17} is I; and X_{26} is K(2-[2-(2-amino-ethoxy)-ethoxy]- acetyl)$_2$-(γ-Glu)-CO-(CH_2)q-CO_2H.

14. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 12 wherein q is 16.

15. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of claims 1 to 12 wherein q is 18.

16. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 1 wherein:

X_1 is Y and Z_1 is absent;

X_2 is selected from the group consisting of Aib and D-Ala; X_6 is F;

X_{13} is selected from the group consisting of αMeL and L;

X_{16} is selected from the group consisting of K and Orn;

X_{18} is selected from the group consisting of H and A; X_{20} is Aib;

X_{22} is F;

X_{24} is selected from the group consisting of E, N, and D-Glu; X_{25} is selected from the group consisting of Y, 4-Pal, and W;

X_{28} is selected from the group consisting of E and A;

X_{29} is selected from the group consisting of G, A, and Q; q is selected from the group consisting of 16 and 18.

17. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 16 wherein:

X_2 is Aib;

X_{13} is αMeL;

X_{18} is H;

X_{24} is selected from the group consisting of E and D-Glu;

X_{25} is selected from the group consisting of Y and 4-Pal;

X_{28} is E;

X_{29} is selected from the group consisting of G and A.

18. A compound or pharmaceutically acceptable salt thereof, as claimed by Claim 17 wherein: X_{17} is K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)$_2$-(γ-Glu)-CO-(CH_2)q-CO_2H; and X_{26} is L.

19. A compound or pharmaceutically acceptable salt thereof, as claimed by Claim 17 wherein: X_{17} is I; and X_{26} is K(2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)$_2$-(γ-Glu)-CO-(CH_2)q-CO2H.

20. A compound, or pharmaceutically acceptable salt thereof, as claimed by

Claim 1 wherein the compound is selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11.

21. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 20 wherein the compound is SEQ ID NO: 7.

22. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 20 wherein the compound is SEQ ID NO:8.

23. A compound, or pharmaceutically acceptable salt thereof, as claimed by Claim 20 wherein the compound is SEQ ID NO:10.

24. A method for treating a condition selected from the group consisting of diabetes mellitus, obesity, and metabolic syndrome, comprising administering to a patient in need thereof, an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 22.

25. A method as claimed by Claim 24 wherein the condition is obesity.

26. A method as claimed by Claim 24 wherein the condition is type 2 diabetes mellitus.

27. A method for treating diabetes in a patient receiving insulin therapy comprising administering an effective amount of a compound or pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 22 to a patient in need thereof.

28. A pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 22 and at least one pharmaceutically acceptable carrier, diluent, or excipient.

29. A compound, or a pharmaceutically acceptable salt thereof, as claimed by any one of Claims 1 to 22 for use in treating a condition selected from the group consisting of diabetes mellitus, obesity, and metabolic syndrome.

30. A compound, or a pharmaceutically acceptable salt thereof, as claimed by Claim 29 wherein the condition is type 2 diabetes mellitus.